ArticleBMJ open2020

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.

Xiaoting Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.